同时使用纤维素可以降低在接受他治疗的中度慢性病患者中的心血管风险吗? 一个队列研究研究
Li-Yi Ma1, Pei-Chun Fan1,2, Chao-Yu Chen1,2
1Kidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333423, Taiwan.
Journal of clinical medicine
|January 11, 2024
概括
在慢性病 (CKD) 患者中,将纤维酸添加到他类药物治疗中,并没有显著减少主要心血管不良事件或全因死亡率. 纤维酸可能不会在中度CKD中提供超出单独使用他类药物的额外心血管保护.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性病 (CKD) 中的高甘油三血症增加了心血管疾病 (CVD) 的风险.
- 类药物是CKD的第一线治疗脂质失调症,但纤维酸的作用尚不清楚.
- 研究在慢性病患者中预防心血管疾病的联合他纤维酸治疗.
研究的目的:
- 为了评估中度慢性病患者同时进行纤维酸和他类药物治疗的疗效.
- 评估对心血管事件和死亡率的影响.
- 为了确定纤维是否提供额外的CVD保护,当与他类药物结合.
主要方法:
- 来自长光研究数据库的CKD3患者的回顾性队列研究.
- 接受他类药物治疗的患者,没有先前的ezetimibe或niacin.
- 纤维酸组 (n=954) 与非纤维酸组 (n=2358) 之间的比较,甘油三含量>200 mg/dL.
主要成果:
- 纤维酸组显示急性心肌梗塞 (AMI) 的发生率明显较低.
- 两组之间在主要不良心血管和脑血管事件中没有发现显著差异.
- 纤维化和非纤维化组之间的所有原因死亡率没有显著差异.
结论:
- 在中度CKD患者中,同时进行纤维酸和他类药物治疗并没有显著降低主要心血管不良事件或全因死亡率.
- 与单独使用他类药物治疗相比,纤维酸可能不会在这个人群中提供额外的心血管保护.
- 需要进一步的研究,以澄清纤维素在控制CKD心血管风险中的作用.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
664
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
664
01:11Renal Failure: Dose Adjustments
92
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
92
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
631
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
631
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
836
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
836